A panelist discusses how graft-vs-host disease (GVHD) manifests through a complex constellation of symptoms affecting ...

McDonald Criteria revisions around 30% of patients with atypical clinical symptoms or radiological-only presentation meet MS ...

Drug development programs face unique challenges in demonstrating the safety and effectiveness of drugs for treating rare diseases. The ...

Title: CONNECT1-EDO51: A 12-Week Open-Label Phase 2 Study to Evaluate PGN-EDO51 Safety and Efficacy in People with Duchenne Amenable to Exon 51 Skipping ...

The presentations will be available in the Publications section of REGENXBIO's website. ABOUT REGENXBIO Inc. REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives ...

Below is a partial transcript, which has been lightly edited for clarity: Sandra Koch, DVM, MS, DACVD: Before I talk about the clinical presentation, I just wanted to briefly mention that feline ...

during an oral presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 16-19, 2025. Presentation Details: Title: ARCUS-Mediated Excision of ...

The oral presentations include data from the ongoing DELIVER clinical trial in Duchenne muscular ... Results from the Real-World IMPaCT Study The FORCE™ Platform Achieves Robust and Durable ...

In order to both ensure that ICTM staff working on clinical trials are properly trained, and also to share the expertise of our staff with those working on clinical trials outside of ICTM, we offer ...